Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University, Japan
Katsuyuki Tanabe, Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate
School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama 700-8558, Japan, Tel: 81-86-235-7235; Email: firstname.lastname@example.org
Received: January 30, 2018; Published: February 13, 2018
Vascular endothelial growth factor (VEGF)-A is well known to be involved in the pathogenesis of diabetic nephropathy. Although it may be
a promising therapeutic target, recent evidence that anti-VEGF therapy induces renal thrombotic micro-angiopathy has tempered interest in its
use. We discuss the necessary conditions for future VEGF-targeting therapy against diabetic nephropathy.